EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Insulet's enterprise value is $12,349 Mil.
Insulet's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $321 Mil. Therefore, Insulet's EV-to-EBITDA for today is 38.43.
The historical rank and industry rank for Insulet's EV-to-EBITDA or its related term are showing as below:
PODD'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -377.86 Med: 127.24 Max: 1919.9
Current: 38.43
During the past 13 years, the highest EV-to-EBITDA of Insulet was 1919.90. The lowest was -377.86. And the median was 127.24.
PODD's EV-to-EBITDA is ranked worse than 85.6% of 486
companies
in the Medical Devices & Instruments industry
Industry Median: 15.12
vs PODD: 38.43
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-28), Insulet's stock price is $166.19.
Insulet's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $2.910. Therefore, Insulet's PE Ratio for today is 57.11.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Insulet EV-to-EBITDA Historical Data
The historical data trend for Insulet's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Insulet's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Insulet's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Insulet's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Insulet's EV-to-EBITDA falls into.
Insulet EV-to-EBITDA Calculation
Insulet's EV-to-EBITDA for today is calculated as:
Insulet's current Enterprise Value is $12,349 Mil.
Insulet's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $321 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Insulet (NAS:PODD) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Insulet's share price for today is $166.19.
Insulet's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.910.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Insulet's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 360,000 insulin-dependent diabetics are using it worldwide.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PODD has been successfully added to your 